A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)

Trial Profile

A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Influenza virus vaccine
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 May 2017 Results presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society
    • 04 Dec 2015 Planned End Date changed from 1 Feb 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 04 Dec 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top